PT-141 (Bremelanotide) #
- Other Names: Bremelanotide, Vyleesi
- Primary Functions and Actions:
- Increases sexual desire in women.
- Treats hypoactive sexual desire disorder (HSDD).
- Mechanism of Action:
- PT-141 is a melanocortin receptor agonist.
- It binds to melanocortin receptors (MC1R and MC4R) in the brain, which can influence sexual function and appetite.
- It increases sexual desire by affecting the central nervous system.
- Systems Activated:
- Nervous System: Influences sexual function.
- Dosage and Timing:
- The recommended dose is 1.75 mg, administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity.
- Do not use more than one dose within 24 hours or more than eight doses per month.
- Contraindications and Side Effects:
- Common side effects include nausea, flushing, headache, and vomiting.
- Contraindicated in individuals with uncontrolled hypertension or known cardiovascular disease.
- Potential Uses:
- Treating hypoactive sexual desire disorder (HSDD) in women
References:
-
- PMID: 15537463, PMID: 14675143
- PMID: 15537463 – [J Sex Med. 2004 Nov;1(3):276-82.] – Double-blind, placebo-controlled study of bremelanotide for the treatment of female sexual dysfunction. https://pubmed.ncbi.nlm.nih.gov/15537463/
- PMID: 14675143 – [Int J Impot Res. 2004 Nov-Dec;16(6):467-75.] – Bremelanotide, a melanocortin receptor agonist, in female sexual dysfunction: a dose-ranging study. https://pubmed.ncbi.nlm.nih.gov/14675143/
Article Summaries: #
PMID: 15537463 #
This study investigated the effects of bremelanotide, a melanocortin receptor agonist, on female sexual dysfunction through a double-blind, placebo-controlled design. The objective was to evaluate the efficacy and safety of bremelanotide in improving sexual desire and overall sexual satisfaction in women experiencing sexual dysfunction.
The results of the study showed that participants taking bremelanotide reported significant improvements in sexual desire, arousal, and satisfaction compared to those receiving a placebo. The findings suggest that bremelanotide effectively enhances sexual function in women with sexual dysfunction.
In conclusion, bremelanotide demonstrates potential as a viable treatment option for female sexual dysfunction. This study’s positive outcomes indicate the need for further research to fully understand the peptide’s mechanisms and long-term benefits in improving women’s sexual health.
PMID: 14675143 #
This article focused on a dose-ranging study of bremelanotide in the treatment of female sexual dysfunction. The researchers aimed to determine the most effective dose that would enhance sexual satisfaction and alleviate dysfunction in women.
The results indicated that various doses of bremelanotide effectively improved sexual desire and response among participants, with some doses showing particularly strong effects. The study concluded that bremelanotide is a promising therapeutic option for addressing female sexual dysfunction, providing beneficial effects on sexual desire and arousal.
In conclusion, this dose-ranging study supports the use of bremelanotide as an effective treatment for improving sexual function in women experiencing sexual dysfunction. The findings warrant further exploration into optimal dosing and long-term effects of bremelanotide for this condition.
